Figure 2.

exNK cells convert lung cancer patient PDL1− tumors to PDL1+/hi. Lung cancer patient tumors were seeded in transwell on apical and basolateral surfaces. exNK cells or rhIFNγ (20 ng/mL) or neither (basal) were added to the apical chamber and incubated for 48 hours. (A) PDL1 TPS and (B) PDL1 mean fluorescence intensity (MFI) on basolateral tumor cells. (C) Representative flow plots of PDL1 on exNK-treated versus untreated patient tumors. (D) Proportion of patient tumors that were PDL1^neg, PDL1^lo or PDL1^hi pre-exNK and post-exNK treatment. (E) Quantification and representative histogram of PDL1 expression on lung cancer patient tumors treated with expanded or unexpanded freshly isolated (fresh) pbNK cells. Data show means±SEM of 5–32 replicates per condition. A, B, E analyzed via one-way ANOVA. *P<0.05; ****p<0.0001. ANOVA, analysis of variance; exNK, expanded natural killer; pbNK, peripheral blood NK; PDL1, programmed death receptor ligand-1; rhIFNγ, recombinant human interferon-gamma; TPS, Tumor Proportion Score.